News

Dx&Vx held discussions on building partnerships with global pharmaceutical and biotech companies at the JP Morgan Healthcare Conference

2024.01.16

| Expect cooperation in all areas, including license-in/out, investment, joint research, companion diagnostics, and genome databases

Dx&Vx has decided to establish collaborative relationships with global companies."

Dx&Vx announced on the 15th that it has agreed to establish various types of cooperative relationships in the future through partnering meetings with about 30 companies, including global pharmaceutical companies, new drug developers, and investment companies, at the 2024 JP Morgan Healthcare Conference and Biotech Showcase 2024 held in San Francisco.

The initial discussions have taken place with global pharmaceutical companies on the introduction of companion diagnostics and genetic testing services for prenatal and newborn genetic information. Collaborative efforts have also been established with drug development companies for the exploration of biomarkers and the provision of essential data for drug development through genomics big data services.



Furthermore, discussions have taken place regarding various forms of investment and technical collaboration, including licensing in/out, joint research on the pipeline under development by Dx&Vx and technologies with anticipated synergies, clinical collaborations, and the domestic introduction of foreign pharmaceuticals. Prospects include the initiation of formal agreements and business collaborations following detailed discussions in the future.

At the biotech showcase, CEO Kwon Kyu-chan was a presenter and discussed various ways to collaborate as he drew high interest from global pharmaceutical bio companies on the pipeline currently being developed, plans to establish a local diagnostic center in Italy, and Healthcare 4.0 emphasized by Lim Jong-yoon, president of Hanmi Pharmaceutical.

Kwon Kyu-chan, CEO of Dx&Vx, said, "During the event, various partnering meetings were held across all business areas, from licensing to joint research to genome databases." "We will not only collaborate on technology with global companies, but also secure various business items to create a year for quantum jumps."

Source:edaily